X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

    INOVIO to Develop dMAb COVID Treatments under DARPA Grant

    Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

    Thermo Fisher Expands Clinical Supply Services in Europe

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    Abzena Invests $60M Into cGMP Manufacturing Capacity

    COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

    The UK begins the biggest ever immunization program

    The UK begins the biggest ever immunization program

    Russia roll out the homegrown Sputnik V vaccine for its population

    Russia roll out the homegrown Sputnik V vaccine for its population

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

    INOVIO to Develop dMAb COVID Treatments under DARPA Grant

    Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

    Thermo Fisher Expands Clinical Supply Services in Europe

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    Abzena Invests $60M Into cGMP Manufacturing Capacity

    COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

    The UK begins the biggest ever immunization program

    The UK begins the biggest ever immunization program

    Russia roll out the homegrown Sputnik V vaccine for its population

    Russia roll out the homegrown Sputnik V vaccine for its population

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19

Content Team by Content Team
12th October 2020
in Clinical Trials, Press Statements
Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19

Vir Biotechnology, Inc. and GlaxoSmithKline plc announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) study evaluating VIR-7831 for the early treatment of COVID-19 in patients who are at high risk of hospitalization. VIR-7831 (also known as GSK4182136) is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody that was selected based on its potential to neutralize the virus, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs (one of the major sites of infection). Following a positive assessment of unblinded safety data from the lead-in portion of the trial by an Independent Data Monitoring Committee on September 30, 2020, the COMET-ICE registrational study will now expand globally to additional sites in North America, South America and Europe.

George Scangos, Ph.D., chief executive officer of Vir, said: “The rapid achievement of this important milestone reflects the urgency with which we’re mobilizing our resources in the hope of preventing the worst consequences of this deadly virus. VIR-7831 is an antibody with characteristics that may enable it to prevent hospitalization or death via multiple mechanisms. We look forward to continuing to collaborate with GSK to accelerate its development.”

Dr. Hal Barron, chief scientific officer and president R&D, GSK, said: “Given the urgent patient need, I am very pleased that we have progressed VIR-7831 from pre-clinical studies to a Phase 3 trial in only six months since announcing our collaboration with Vir. We believe this neutralizing antibody’s high barrier to resistance, notable effector function and enhanced delivery into the lung suggest it has best-in-class potential in the fight against this global pandemic.”

The Phase 3 portion of the COMET-ICE study will assess the safety and efficacy of a single intravenous infusion of VIR-7831 or placebo in approximately 1,300 non-hospitalized participants globally (670 patients in the treatment arm and approximately 670 patients in the placebo arm). The primary efficacy endpoint is the proportion of patients who have progression of COVID-19 as defined by the need for hospitalization or death within 29 days of randomization. Interim analyses are planned to evaluate safety, futility and efficacy, the results of which may be available as early as the end of 2020. Results for the primary endpoint are expected in the first quarter of 2021, with current estimates at January 2021.

The COMET clinical development program for VIR-7831 includes two additional planned trials – one for the treatment of hospitalized patients and another for the prevention of symptomatic infection. The companies also expect to start a Phase 1b/2a trial in the second half of 2020 evaluating VIR-7832, a second investigational SARS-CoV-2 neutralizing antibody that shares the same characteristics as VIR-7831, plus enhanced effector function, which may confer additional efficacy in treatment or prophylaxis by stimulating a T-cell response.

About VIR-7831 / GSK4182136
VIR-7831 (GSK4182136) is a monoclonal antibody that has shown the ability to neutralize SARS-CoV-2 live virus in vitro and in vivo. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (also known as SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. VIR-7831/GSK4182136 has been engineered with the potential to enhance lung bioavailability and have an extended half-life.

About VIR-7832
VIR-7832 is a monoclonal antibody that has shown the ability to neutralize SARS-CoV-2 live virus in vitro. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (also known as SARS), indicating that the epitope is highly conserved, which may make it more difficult for escape mutants to develop. VIR-7832 has been engineered with the potential to enhance lung bioavailability, have an extended half-life, and function as a therapeutic and/or prophylactic T cell vaccine.

About the Vir and GSK Collaboration
In April 2020, Vir and GSK entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.

About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. For more information, please visit www.vir.bio.

About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

Previous Post

CureVac initiates Phase 2a clinical trial of COVID-19 vaccine candidate

Next Post

Good nutrition can contribute to keeping COVID-19 and other diseases away

Related Posts

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Drug Development

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

17th December 2020
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
Drug Development

INOVIO to Develop dMAb COVID Treatments under DARPA Grant

17th December 2020
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing
Clinical Trials

Thermo Fisher Expands Clinical Supply Services in Europe

17th December 2020
DuPont Brings Science-backed Quality and Innovation to Asia's Pharmaceutical Industry at CPhI China 2020
Press Statements

DuPont Brings Science-backed Quality and Innovation to Asia’s Pharmaceutical Industry at CPhI China 2020

14th December 2020
Pakistanis join final trials for China-made vaccine
Clinical Trials

Pakistanis join final trials for China-made vaccine

26th November 2020
Air France KLM Martinair Cargo partners with SkyCell to increase sustainability and safety of pharmaceutical shipments
Packaging & Logistic

Air France KLM Martinair Cargo partners with SkyCell to increase sustainability and safety of pharmaceutical shipments

26th November 2020
Next Post
Good nutrition can contribute to keeping COVID-19 and other diseases away

Good nutrition can contribute to keeping COVID-19 and other diseases away

Latest News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

17th December 2020
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Drug Development

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

17th December 2020
Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery
Drug Development

Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

17th December 2020
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
Drug Development

INOVIO to Develop dMAb COVID Treatments under DARPA Grant

17th December 2020
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing
Clinical Trials

Thermo Fisher Expands Clinical Supply Services in Europe

17th December 2020
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In